Protocol Ledger

NCT05135091 · Phase III · RECRUITING

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

Interventional Phase III clinical trial protocol NCT05135091 sponsored by Neurona Therapeutics in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-16 Enrollment: 88 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05135091
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)88 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05135091
Protocol FieldVerified Registry Value
NCT IdentifierNCT05135091
Consolidated Lead SponsorNeurona Therapeutics
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment88 participants (ESTIMATED)
Registered Start Date2022-06-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI